Pacira BioSciences
PCRX
36.48
0.00
0.00%
Pacira BioSciences
US · PCRX
#3244 by market cap
36.48
0.00
0.00%
Periodic snapshot; not a real-time feed.
· 2026-11-19 19:54
Quant vs Street three independent views, side by side
StockVane factor grade
C-
Momentum strategy signal
Hold
Analyst consensus
Hold
All 3 views agree: neutral.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
1 4
■ Upgrades■ Downgrades
- 1 upgrade vs 4 downgrades among tracked analyst rating changes.
- The single most recent change was actually an upgrade (J.P. Morgan moved from Sell to Hold on 2026-10-12), though the broader window skews toward downgrades.
Analyst consensus 9 analysts
Hold
Avg price target 34.79 -4.6%
Price target rangecurrent 36.48
Low25.00
Avg34.79
High36.50
Buy 0%
Hold 100%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-12 | J.P. Morgan | -- | Hold | 36.50 |
| 2026-10-09 | Truist Financial | -- | Hold | 36.50 |
| 2026-10-09 | Leerink Partners | -- | Hold | 36.50 |
| 2026-10-09 | H.C. Wainwright | -- | Hold | 36.50 |
| 2026-10-08 | Jefferies | -- | Hold | 36.00 |
| 2026-10-08 | Needham | -- | Hold | -- |
| 2026-10-08 | Oppenheimer | -- | Hold | -- |
| 2026-10-08 | RBC Capital | -- | Hold | 36.50 |
| 2026-10-07 | Truist Financial | -- | Buy | 31.00 |
| 2026-10-05 | Needham | -- | Buy | 33.00 |
| 2026-09-23 | Oppenheimer | -- | Buy | 32.00 |
| 2026-09-21 | Truist Financial | -- | Buy | -- |
| 2026-09-09 | Leerink Partners | -- | Hold | 28.00 |
| 2026-08-24 | Truist Financial | -- | Buy | -- |
| 2026-08-17 | Barclays | -- | Hold | 25.00 |
| 2026-08-10 | J.P. Morgan | -- | Sell | 23.00 |
| 2026-08-05 | Needham | -- | Buy | 33.00 |
| 2026-08-05 | H.C. Wainwright | -- | Buy | 38.00 |
| 2026-07-27 | Needham | -- | Buy | 32.00 |
| 2026-07-01 | H.C. Wainwright | -- | Buy | 38.00 |
| 2026-06-30 | Needham | -- | Buy | 32.00 |
| 2026-05-14 | Barclays | -- | Hold | 25.00 |
| 2026-05-04 | H.C. Wainwright | -- | Buy | 38.00 |
| 2026-05-01 | Truist Financial | -- | Buy | -- |
| 2026-05-01 | Needham | -- | Buy | 32.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-10-12 | J.P. Morgan | Sell → Hold | 36.50 |
| 2026-10-09 | Truist Financial | Buy → Hold | 36.50 |
| 2026-10-09 | H.C. Wainwright | Buy → Hold | 36.50 |
| 2026-10-08 | Needham | Buy → Hold | -- |
| 2026-10-08 | Oppenheimer | Buy → Hold | -- |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-04 | After close | ±10.97% | -9.96% (in line) |
| 2026/Q1 | 2026-04-30 | After close | ±12.16% | -4.12% (in line) |
| 2025/Q4 | 2026-02-26 | After close | ±13.06% | -3.01% (in line) |
| 2025/Q3 | 2025-11-06 | After close | ±16.48% | +4.50% (in line) |
| 2025/Q2 | 2025-08-05 | After close | ±11.84% | -0.62% (in line) |
| 2025/Q1 | 2025-05-08 | After close | ±12.22% | +0.84% (in line) |
| 2024/Q4 | 2025-02-27 | After close | ±14.83% | -5.24% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±13.30% | +0.17% (in line) |
| 2024/Q2 | 2024-07-30 | After close | ±36.63% | +5.68% (in line) |
| 2024/Q1 | 2024-05-07 | After close | ±12.41% | +11.84% (in line) |
| 2023/Q4 | 2024-02-29 | -- | ±14.93% | -0.64% (in line) |
| 2023/Q3 | 2023-11-02 | -- | ±7.14% | +3.11% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-19 19:54:59 · For reference only, not investment advice and not tailored to your situation.
Pacira BioSciences discussion 0 comments